Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1979;60:492-496

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harker, L. A.
Right arrow Articles by Hazzard, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harker, L. A.
Right arrow Articles by Hazzard, W.

Circulation, Vol 60, 492-496, Copyright © 1979 by American Heart Association


ARTICLES

Platelet kinetic studies in patients with hyperlipoproteinemia: effects of clofibrate therapy

LA Harker and W Hazzard

Studies of platelet and fibrinogen kinetics in 27 patients with hyperlipoproteinemia and 28 control subjects demonstrated shortened platelet survival and increased platelet turnover in seven patients with type III and 10 patients with type IV-V hyperlipoproteinemia (p less than 0.01). There was no correlation between platelet survival time and specific lipid levels, vascular disease, sex or age. Platelet kinetics were not significantly altered from control values in eight patients with familial hypercholesterolemia. Platelet aggregation studies and fibrinogen kinetic measurements did not differ in any of the hyperlipoproteinemic groups of patients from those in control subjects. Despite significant changes in plasma lipids induced by clofibrate, platelet survival was significantly extended only in patients with type IV-V hyperlipoproteinemia (p less than 0.05). These results are consistent with the hypothesis that atherogenesis in patients with types III--V hyperlipoproteinemia may be associated with a process of endothelial desquamation, and type IIa hyperlipoproteinemia may involve nondesquamating endothelial injury.


This article has been cited by other articles:


Home page
Arch Intern MedHome page
M. L. Zucker, C. Trowbridge, J. Woodroof, S. B. Chernoff, L. Reynoso, and C. A. Dujovne
Low- vs High-Dose Aspirin: Effects on Platelet Function in Hyperlipoproteinemic and Normal Subjects
Arch Intern Med, May 1, 1986; 146(5): 921 - 925.
[Abstract] [PDF]


Home page
JAMAHome page
D. E. Hammerschmidt
Platelets and the Environment
JAMA, January 15, 1982; 247(3): 345 - 350.
[Abstract] [PDF]